全文获取类型
收费全文 | 36254篇 |
免费 | 2384篇 |
国内免费 | 88篇 |
专业分类
耳鼻咽喉 | 327篇 |
儿科学 | 906篇 |
妇产科学 | 670篇 |
基础医学 | 5917篇 |
口腔科学 | 636篇 |
临床医学 | 3863篇 |
内科学 | 6669篇 |
皮肤病学 | 694篇 |
神经病学 | 3138篇 |
特种医学 | 1396篇 |
外国民族医学 | 2篇 |
外科学 | 5169篇 |
综合类 | 330篇 |
一般理论 | 37篇 |
预防医学 | 3571篇 |
眼科学 | 652篇 |
药学 | 2569篇 |
中国医学 | 47篇 |
肿瘤学 | 2133篇 |
出版年
2023年 | 158篇 |
2022年 | 270篇 |
2021年 | 700篇 |
2020年 | 447篇 |
2019年 | 616篇 |
2018年 | 719篇 |
2017年 | 601篇 |
2016年 | 693篇 |
2015年 | 822篇 |
2014年 | 1086篇 |
2013年 | 1464篇 |
2012年 | 2282篇 |
2011年 | 2330篇 |
2010年 | 1305篇 |
2009年 | 1296篇 |
2008年 | 2082篇 |
2007年 | 2233篇 |
2006年 | 2080篇 |
2005年 | 2056篇 |
2004年 | 1970篇 |
2003年 | 1869篇 |
2002年 | 1744篇 |
2001年 | 691篇 |
2000年 | 605篇 |
1999年 | 616篇 |
1998年 | 386篇 |
1997年 | 312篇 |
1996年 | 297篇 |
1995年 | 218篇 |
1994年 | 234篇 |
1993年 | 202篇 |
1992年 | 286篇 |
1991年 | 342篇 |
1990年 | 292篇 |
1989年 | 306篇 |
1988年 | 272篇 |
1987年 | 265篇 |
1986年 | 267篇 |
1985年 | 271篇 |
1984年 | 187篇 |
1983年 | 183篇 |
1982年 | 126篇 |
1980年 | 123篇 |
1979年 | 199篇 |
1978年 | 139篇 |
1977年 | 127篇 |
1975年 | 149篇 |
1974年 | 152篇 |
1973年 | 137篇 |
1972年 | 135篇 |
排序方式: 共有10000条查询结果,搜索用时 812 毫秒
991.
992.
Berti-Couto Sde A Couto-Souza PH Jacobs R Nackaerts O Rubira-Bullen IR Westphalen FH Moysés SJ Ignácio SA Costa MB Tolazzi AL 《Journal of applied oral science : revista FOB》2012,20(2):157-161
Objective
The aim of this study was to evaluate the effectiveness of clinical criteria for the diagnosis of hyposalivation in hospitalized patients.Material and Methods
A clinical study was carried out on 145 subjects (48 males; 97 females; aged 20 to 90 years). Each subject was clinically examined, in the morning and in the afternoon, along 1 day. A focused anamnesis allowed identifying symptoms of hyposalivation, like xerostomia complaints (considered as a reference symptom), chewing difficulty, dysphagia and increased frequency of liquid intake. Afterwards, dryness of the mucosa of the cheecks and floor of the mouth, as well as salivary secretion during parotid gland stimulation were assessed during oral examination.Results
Results obtained with Chi-square tests showed that 71 patients (48.9%) presented xerostomia complaints, with a significant correlation with all hyposalivation symptoms (p<0.05). Furthermore, xerostomia was also significantly correlated with all data obtained during oral examination in both periods of evaluation (p<0.05).Conclusion
Clinical diagnosis of hyposalivation in hospitalized patients is feasible and can provide an immediate and appropriate therapy avoiding further problems and improving their quality of life. 相似文献993.
I Bendit SS Sanabani M Conchon M Serpa MM Novaes L Nardinelli TD Pereira L Tucunduva PD Ferreira PE Dorlhiac-Llacer DD Fischer Chamone 《Acta haematologica》2012,128(4):223-232
Here we compare the management and survival outcomes of chronic myeloid leukemia (CML) patients who had early or late imatinib mesylate (IM) therapy. The cytogenetic and molecular responses of 189 CML patients were analyzed. Of this group, 121 patients were classified as the early chronic phase (ECP) group and started IM within 12 months of diagnosis. The other 68 patients were classified as the late chronic phase (LCP) group who had been treated with interferon (IFN)-alpha-2 and crossed over to IM more than 12 months after diagnosis. The overall rates of complete cytogenetic response (CCyR) and major molecular response (MMR) at last follow-up were 83.6 and 78.1% in the ECP and LCP groups, respectively. The CCyR rates were 89.3 (for ECP patients) versus 73.5% (for LCP patients; p < 0.0001). At last follow-up, 82.4% ECP and 64.2% LCP patients had achieved an MMR (p < 0.0001). No significant differences were noted between the two groups with regard to survival outcomes. Our experience reveals that IM is an effective rescue therapy in most CML LCP patients who are intolerant or in whom IFN-alpha therapy fails. Such therapeutic options should be considered in LCP patients, particularly in countries where IM may not be available. 相似文献
994.
995.
996.
997.
Hamilton E Pearce L Morgan L Robinson S Ware V Brennan P Thomas NS Yallop D Devereux S Fegan C Buggins AG Pepper C 《British journal of haematology》2012,158(5):589-599
Interactions in the tumour microenvironment can promote chronic lymphocytic leukaemia (CLL) cell survival, proliferation and drug resistance. A detailed comparison of three co-culture systems designed to mimic the CLL lymph node and vascular microenvironments were performed; two were mouse fibroblast cell lines transfected with human CD40LG or CD31 and the third was a human microvascular endothelial cell line, HMEC-1. All three co-culture systems markedly enhanced CLL cell survival and induced a consistent change in CLL cell phenotype, characterized by increased expression of CD38, CD69, CD44 and ITGA4 (CD49d); this phenotype was absent following co-culture on untransfected mouse fibroblasts. In contrast to HMEC-1 cells, the CD40LG and CD31-expressing fibroblasts also induced ZAP70 expression and marked CLL cell proliferation as evidenced by carboxyfluorescein succinimidyl ester labelling and increased Ki-67 expression. Taken together, our data show that co-culture on different stroma induced a remarkably similar activation phenotype in CLL cells but only the CD40LG and CD31-expressing fibroblasts increased ZAP70 expression and CLL cell proliferation, indicating that ZAP70 may play a critical role in this process. This comparative study reveals a number of striking similarities between the co-culture systems tested but also highlights important differences that should be considered when selecting which system to use for in-vitro investigations. 相似文献
998.
Zirm E Spies-Weisshart B Heidel F Schnetzke U Böhmer FD Hochhaus A Fischer T Scholl S 《British journal of haematology》2012,157(4):483-492
Fms-like tyrosine kinase (FLT3) mutations are the most frequent mutations in patients with acute myeloid leukaemia (AML) that confer a poor prognosis. Constitutively active FLT3-ITD (internal tandem duplications) mutations define a promising target for therapeutic approaches using small molecule inhibitors. However, several point mutations of the FLT3 tyrosine kinase domain (FLT3-TKD) have been identified to mediate resistance towards FLT3 tyrosine kinase inhibitors (FLT3-TKI), including secondary mutations of FLT3. We investigated the cellular effects of the recently characterised FLT3-TKI ponatinib (AP24534) on murine myeloid cells transfected with FLT3-ITD with or without additional point mutations of the FLT3-TKD including the (so far) multi-resistant F691I mutation. Ponatinib effectively induced apoptosis not only in the parental FLT3-ITD cell line but also in all stably transfected subclones harbouring additional FLT3-TKD point mutations (N676D, F691I or G697R). These observations correlated with a strong inhibition of FLT3-ITD and its downstream targets STAT5, AKT and ERK1/2 upon ponatinib incubation, as determined by Western blotting. We conclude that ponatinib represents a promising FLT3-TKI that should be further investigated in clinical trials. The targeted therapy of FLT3-ITD-positive AML with ponatinib might be associated with a lower frequency of secondary resistance caused by acquired FLT3-TKD mutations. 相似文献
999.
1000.
M Reincke E Fischer S Gerum K Merkle S Schulz A Pallauf M Quinkler G Hanslik K Lang S Hahner B Allolio C Meisinger R Holle F Beuschlein M Bidlingmaier S Endres;Participants of the German Conn's Registry-Else Kröner-Fresenius-Hyperaldosteronism Registry 《Hypertension》2012,60(3):618-624
In comparison with essential hypertension, primary aldosteronism (PA) is associated with an increased risk of cardiovascular morbidity. To date, no data on mortality have been published. We assessed mortality of patients treated for PA within the German Conn's registry and identified risk factors for adverse outcome in a case-control study. Patients with confirmed PA treated in 3 university centers in Germany since 1994 were included in the analysis. All of the patients were contacted in 2009 and 2010 to verify life status. Subjects from the population-based F3 survey of the Cooperative Health Research in the Region of Augsburg served as controls. Final analyses were based on 600 normotensive controls, 600 hypertensive controls, and 300 patients with PA. Kaplan-Meyer survival curves were calculated for both cohorts. Ten-year overall survival was 95% in normotensive controls, 90% in hypertensive controls, and 90% in patients with PA (P value not significant). In multivariate analysis, age (hazard ratio, 1.09 per year [95% CI, 1.03-1.14]), angina pectoris (hazard ratio, 3.6 [95% CI, 1.04-12.04]), and diabetes mellitus (hazard ratio, 2.55 [95% CI, 1.07-6.09]) were associated with an increase in all-cause mortality, whereas hypokalemia (hazard ratio, 0.41 per mmol/L [95% CI, 0.17-0.99]) was associated with reduced mortality. Cardiovascular mortality was the main cause of death in PA (50% versus 34% in hypertensive controls; P<0.05). These data indicate that cardiovascular mortality is increased in patients treated for PA, whereas all-cause mortality is not different from matched hypertensive controls. 相似文献